CEP
CPRX

Chicago Equity Partners’s Catalyst Pharmaceutical CPRX Stock Holding History

Chicago Equity Partners’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-54,440
Closed -$204K – 699
2019
Q4 		$204K Sell
54,440
-108,570
-67% -$508K 0.01% 825
2019
Q3 		$866K Sell
163,010
-390
-0.2% -$2.08K 0.04% 537
2019
Q2 		$627K Buy
+163,400
New +$706K 0.03% 652

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Chicago Equity Partners's CPRX Position: Q1 2020 in Review

Chicago Equity Partners sold out of Catalyst Pharmaceutical (CPRX) in Q1 2020, closing a stake of 54,440 shares — an estimated $204K sold.

Chicago Equity Partners first reported a position in CPRX in Q2 2019 and held it in 3 quarters. The position peaked at $866K in Q3 2019. 131 funds tracked by Wall St. Rank hold CPRX as of Q1 2020.

  • Chicago Equity Partners reported no remaining Catalyst Pharmaceutical position as of Q1 2020 after selling out during the quarter.
  • Chicago Equity Partners sold 54,440 Catalyst Pharmaceutical shares in Q1 2020, an estimated $204K.
  • Chicago Equity Partners first reported a position in Catalyst Pharmaceutical in Q2 2019 and held it in 3 quarters.
  • Chicago Equity Partners's Catalyst Pharmaceutical position peaked at $866K in Q3 2019.
  • 131 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2020.

Based on Chicago Equity Partners's 13F filing for Q1 2020, filed 6 May 2020.